When asked during a recent interview if she had any addictions, actress Jennifer Aniston admitted to just one: eye drops. That sounded familiar to Shire execs…

Medivation CEO David Hung fought hard for higher buyout bids. Now, he's set to collect more than $350 million when Pfizer closes its $14 billion deal.

Respiratory player Vectura can set aside its hopes of snagging a COPD indication for ICS/LABA med Flutiform--at least, for now.

Put another tally in Novartis’ biosimilar win column. The company’s Sandoz generics unit has another FDA approval in hand, this time for its copy of Amgen’s…

Pharma mergers might boost profits. But long-term value? Think again, because big mergers hurt innovation. That’s the claim--and now, researchers have some…

Tuesday, Portola unveiled some solid data for its next-gen anticoagulant reversal agent that may help soften the blow of a recent FDA rejection.

As EU regulators demanded $14.5 billion in back taxes from Apple, a U.S. advocacy group was fighting for similar justice for Gilead--but it wants the U.S. to…

Amgen notched up data for a new Prolia use that could amp up the blockbuster-in-the-making, at a time when the company is bracing for biosimilar rivals to its…